Role of Macrophages in Host Resistance Against Tumors

  • William E. Fogler
  • Isaiah J. Fidler
Part of the Cancer Treatment and Research book series (CTAR, volume 14)


The most devastating aspect of cancer is the propensity of malignant neoplasms to spread from their primary site of growth to distant organs where secondary tumors, metastases, can develop. Despite remarkable advances in aggressive adjuvant therapy and improvements in general patient care, most deaths of patients with solid cancers are caused by metastases. There are several reasons for the current failure to eradicate metastasis. First, by the time of surgical excision of the primary neoplasm, metastases may have already occurred. Second, even when metastases are diagnosed, their location and number may limit the effective dose of therapeutic agent that can be delivered to the lesion without being toxic to the host. Third, the most formidable obstacle to successful treatment of metastasis is the heterogeneous nature of malignant neoplasms and the rapid emergence of metastases that are resistant to conventional therapeutic regimens [1–3].


Leukemia Adenocarcinoma Tuberculosis Oncol Bacillus 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fidler IJ: Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res 37:2481–2486, 1978.Google Scholar
  2. 2.
    Poste G, Fidler IJ: The pathogenesis of cancer metastasis. Nature 283:139–146, 1979.Google Scholar
  3. 3.
    Fidler IJ, Kripke ML: Biological variability within murine neoplasms. Antibiot Chemother 28:123–129, 1980.Google Scholar
  4. 4.
    Hart IR, Fidler IJ: The implications of tumor heterogeneity for studies on the biology and therapy of cancer metastasis. Biochim Biophys Acta 651:37–50, 1981.PubMedGoogle Scholar
  5. 5.
    Fidler IJ, Gersten DM, Hart IR: The biology of cancer invasion and metastasis. Adv Cancer Res 28:149–250, 1978.PubMedGoogle Scholar
  6. 6.
    Sugarbaker EV: Cancer metastasis: A product of tumor-host interactions. Curr Probl Cancer 7:3–59, 1979.Google Scholar
  7. 7.
    Evans R, Alexander P: Rendering macrophages specifically cytotoxic by a factor released from immune lymphoid cells. Transplantation 12:227–229, 1971.PubMedGoogle Scholar
  8. 8.
    Evans R, Grant CK, Cox H, Steele K, Alexander P: Thymus-derived lymphocytes produce an immunologically specific macrophage-arming factor. J Exp Med 136:1318–1322,Google Scholar
  9. 9.
    Henney C: On the mechanism of T-cell mediated cytolysis. Transplant Rev 17: 37–70, 1973.PubMedGoogle Scholar
  10. 10.
    Hellstrom KE, Hellstrom I: Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol 18:209–277, 1974.PubMedGoogle Scholar
  11. 11.
    Herberman RB, Holden HT: Natural cell-mediated immunity. Adv Cancer Res 27: 305–377, 1978.PubMedGoogle Scholar
  12. 12.
    Hanna N, Fidler IJ: Role of natural killer cells in the destruction of circulating tumor emboli. JNCI 65: 801–809, 1980.PubMedGoogle Scholar
  13. 13.
    Stutman O, Paige CJ, Figarella EF: Natural cytotoxic cells against solid tumors in mice. I. Strain and age distribution and target cell susceptibility. J Immunol 121: 1819–1826, 1978.PubMedGoogle Scholar
  14. 14.
    Paige CJ, Figarella EF, Cuttito MJ, Cahan A, Stutman O: Natural cytotoxic cells against solid tumors in mice: II. Some characteristics of the effector cells against solid tumors in mice. J Immunol 121: 1827–1835, 1978.PubMedGoogle Scholar
  15. 15.
    Gorer PA, O’Gorman P: The cytotoxic activity of isoantibodies in mice. Transplant Bull 3: 142–145, 1956.Google Scholar
  16. 16.
    Gorer P, Amos DB: Passive immunity of mice against C57BL leukosis EL4 by means of 180 immune serum. Cancer Res 16: 338–343, 1956.PubMedGoogle Scholar
  17. 17.
    Irie K, Irie RF, Morton DL: Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science 186: 454–456, 1974.PubMedGoogle Scholar
  18. 18.
    Bodurtha AJ, Chee DO, Laucius JF, Mastrangelo MJ, Prehn RT: Clinical and immunological significance of human melanoma cytotoxic antibody. Cancer Res 35: 189–193, 1975PubMedGoogle Scholar
  19. 19.
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666–3670, 1975.PubMedGoogle Scholar
  20. 20.
    Green S, Dobrjansky A, Chiasso MA, Carswell E, Schwartz MK, Old LJ: Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst 59: 1519–1522, 1977.PubMedGoogle Scholar
  21. 21.
    Kolb WP, Granger GA: Lymphocyte in vitro cytotoxicity: Characterization of mouse lymphotoxin. Cell Immunol 1: 122–132, 1970.PubMedGoogle Scholar
  22. 22.
    Vailleur D, Donner M, Vailleur J, Burg C: Release of lymphotoxins by spleen cells sensitized against mouse tumor associated antigens. Cell Immunol 6: 466–472, 1973.Google Scholar
  23. 23.
    Heppner G, Miller BE: Biological variability of mouse mammary neoplasms. In: Design of models for testing cancer therapeutic agents, Fidler IJ, White RJ (eds). New York: Van Nostrand, 1981, pp 37–49.Google Scholar
  24. 24.
    Kim U: Metastasizing mammary carcinomas in rats: Induction and study of their immunogenicity. Science 167: 72–74, 1970.PubMedGoogle Scholar
  25. 25.
    Wexler H, Chretien PB, Ketcham AS, Sindelar WF: Induction of pulmonary metastasis in both immune and nonimmune mice: Effect of the removal of a transplanted primary tumor. Cancer 36: 2042–2047, 1975.PubMedGoogle Scholar
  26. 26.
    Fidler IJ, Gersten DM, Riggs CW: Relationship of host immune status to tumor cell arrest, distribution, and survival in experimental metastasis. Cancer 40: 46–54, 1977.PubMedGoogle Scholar
  27. 27.
    Milas L, Hunter N, Mason K, Withers HR: Immunological resistance to pulmonary metastases in C3Hf/Bu mice bearing syngeneic fibrosarcoma of different sizes. Cancer Res 34: 61–71, 1974.PubMedGoogle Scholar
  28. 28.
    Gershon RK, Carter RL, Kondo K: On concomitant immunity in tumour-bearing hamsters. Nature 213: 674–676, 1967.PubMedGoogle Scholar
  29. 29.
    Deodhar SD, Crile G, Jr.: Enhancement of metastases by antilymphocyte serum in allogeneic murine tumor system. Cancer Res 29: 776–779, 1969.PubMedGoogle Scholar
  30. 30.
    Gershon RK, Carter RL: Facilitation of metastatic growth by antilymphocyte serum. Nature 226: 368–370, 1970.PubMedGoogle Scholar
  31. 31.
    Vaage J, Chen K, Merrick S: Effect of immune status on the development of artificially induced metastases in different anatomical locations. Cancer Res 31: 496–500, 1971.PubMedGoogle Scholar
  32. 32.
    Vaage J: Humoral and cellular immune factors in the systemic control of artifically induced metastases in C3Hf mice. Cancer Res 33: 1957–1965, 1973.PubMedGoogle Scholar
  33. 33.
    Fisher ER: Role of thymus in skin and tumor transplantation in the rat. Lab Invest 14: 546–552, 1965.PubMedGoogle Scholar
  34. 34.
    Fidler IJ: Immune stimulation-inhibition of experimental cancer metastasis. Cancer Res 34: 491–498, 1974.PubMedGoogle Scholar
  35. 35.
    Umiel T, Trainin N: Immunological enhancement of tumor growth by syngeneic thymus-derived lymphocytes. Transplantation 18: 244–250, 1974.PubMedGoogle Scholar
  36. 36.
    Hewitt HB, Blake ER, Walder AS: A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br J Cancer 33: 241–259, 1976.PubMedGoogle Scholar
  37. 37.
    Vaage J: A survey of the growth characteristics of, and host reactions to, one hundred C3H/He mammary carcinomas. Cancer Res 38: 331–338, 1978.PubMedGoogle Scholar
  38. 38.
    Hager C, Miller FR, Heppner GH: Influence of serial transplantation on the immunological-clinical correlates of BALB/cf C3H mouse mammary tumors. Cancer Res 38: 2492–2498, 1978.PubMedGoogle Scholar
  39. 39.
    Fidler IJ, Gersten DM, Kripke ML: Influence of immune status on the metastasis of three murine fibrosarcomas of different immunogenicities. Cancer Res 39: 3816–3821, 1979.PubMedGoogle Scholar
  40. 40.
    Prehn RT: Cancer antigens in tumors induced by chemicals. Fed Proc 24: 1018–1028, 1965.PubMedGoogle Scholar
  41. 41.
    Prehn RT: Analysis of antigenic heterogeneity within individual 3-methylcholanthrene- induced mouse sarcomas. J Natl Cancer Inst 45: 1039–1044, 1970.PubMedGoogle Scholar
  42. 42.
    Sugarbaker EV, Cohen AM: Altered antigenicity in spontaneous pulmonary metastases from an antigenic murine sarcoma. Surgery 72: 155–166, 1972.PubMedGoogle Scholar
  43. 43.
    Faraci RP: In vitro demonstration of altered antigenicity of metastases from a primary methylcholanthrene-induced sarcoma. Surgery 76:469–473, 1974.Google Scholar
  44. 44.
    Goldman LI, Flaxman BA, Wernick G, Zabriski JB: Immune surveillance and tumor dissemination: In vitro comparison of the B16 melanoma in primary and metastatic form. Surgery 76: 50–56, 1974.PubMedGoogle Scholar
  45. 45.
    Killion JJ, Kollmorgen GM: Isolation of immunogenic tumor cells by cell-affinity chromatography. Nature 259: 674–676, 1976.PubMedGoogle Scholar
  46. 46.
    Fidler IJ, Gersten DM, Budman MB: Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity. Cancer Res 36: 3160–3165, 1976.PubMedGoogle Scholar
  47. 47.
    Byers WS, Johnston JO: Antigenic differences among osteogenic sarcoma tumor cells taken from different locations in human tumors. Cancer Res 37: 3173–3183, 1977.PubMedGoogle Scholar
  48. 48.
    Biddison WE, Palmer JC: Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y. Proc Natl Acad Sci USA 74: 329–333, 1977.PubMedGoogle Scholar
  49. 49.
    Fidler IJ, Bucana C: Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes. Cancer Res 37: 3945–3956, 1977.PubMedGoogle Scholar
  50. 50.
    Fugi H, Michich E, Pressman D: Differential tumor immunogenicity of L1210 and its sublines. J Immunol 119: 983–986, 1977.Google Scholar
  51. 51.
    Killion JJ: Immunotherapy with tumor subpopulations: I. Active, specific immunotherapy of LI210 leukemia. Cancer Immunol Immunother 4: 115–119, 1978.Google Scholar
  52. 52.
    Kripke ML, Gruys E, Fidler IJ: Metastatic heterogeneity of cells from an ultraviolet light-induced murine fibrosarcoma of recent origin. Cancer Res 38: 2962–2967, 1978.PubMedGoogle Scholar
  53. 53.
    Miller FR, Heppner GH: Immunologic heterogeneity of tumor cell subpopulations from a single mouse mammary tumor. JNCI 63: 1457–1463, 1979.PubMedGoogle Scholar
  54. 54.
    Kolb E, Muller E: Local responses in primary and secondary human lung cancers: II. Clinical conclusions. Br J Cancer 40: 410–416, 1979.PubMedGoogle Scholar
  55. 55.
    Kerbel RS: Implications of immunological heterogeneity of tumors. Nature 280: 358–360, 1979.PubMedGoogle Scholar
  56. 56.
    Schirmacher V, Bosslet K, Shantz G, Claver K, Hubsch D: Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice: IV. Antigenic differences between a metastasizing variant and the parental tumor line revealed by cytotoxic T lymphocytes. Int J Cancer 23: 245–252, 1979.Google Scholar
  57. 57.
    Olsson L, Ebbesen P: Natural polyclonality of spontaneous AKR leukemia and its consequence for so-called specific immunotherapy. JNCI 62: 623–627, 1979.PubMedGoogle Scholar
  58. 58.
    DeWys WD: Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 32: 374–379, 1972.PubMedGoogle Scholar
  59. 59.
    Schabel FM: Concepts for systemic treatment of micrometastases. Cancer 35: 15–24, 1975.PubMedGoogle Scholar
  60. 60.
    Cifone MA, Kripke ML, Fidler IJ: Growth rate and chromosome number of tumor cell lines with different metastatic potential. J Supramol Struct 11: 467–476, 1979.PubMedGoogle Scholar
  61. 61.
    Cifone MA, Fidler IJ: Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci USA 77: 1039–1043, 1980.PubMedGoogle Scholar
  62. 62.
    Miller BE, Miller FR, Leith J, Heppner GH: Growth interaction in vivo between tumor subpopulations derived from a single mouse mammary tumor. Cancer Res 40: 3977–3981, 1980.PubMedGoogle Scholar
  63. 63.
    Gray JM, Pierce GB: Relationship between growth rate and differentiation of melanoma in vivo. J Natl Cancer Inst 32: 1201–1211, 1964.PubMedGoogle Scholar
  64. 64.
    Niles RM, Makarski JS: Hormonal activation of adenylate cyclase in mouse melanoma metastatic variants. J Cell Physiol 96: 351–359, 1978.Google Scholar
  65. 65.
    Fidler IJ, Gruys E, Cifone MA, Barnes Z, Bucana C: Demonstration of multiple phenotypic diversity in a murine melanoma of recent origin. JNCI 67: 947–956, 1981.PubMedGoogle Scholar
  66. 66.
    Ito E, Moore GE: Characteristic differences in clones isolated from an S37 ascites tumor in vitro. Exp Cell Res 48: 440–447, 1967.PubMedGoogle Scholar
  67. 67.
    Mittleman F: The chromosomes of fifty primary Rous rat sarcomas. Hereditas 69: 155–186, 1971.Google Scholar
  68. 68.
    Ohno S: Genetic implication of karyological instability of malignant somatic cells. Physiol Rev 51: 496–526, 1971.Google Scholar
  69. 69.
    Bohm N, Sondritter W: DNA in human tumors: A cytophotometric study. Curr Top Pathol 60: 152–219, 1975.Google Scholar
  70. 70.
    Vindelov LV: Flow microfluoremetric analysis of nuclear DNA in cells from solid tumors and cell suspensions. Virchows Arch [Cell Pathol] 24: 227–242, 1977.Google Scholar
  71. 71.
    Siracky J: An approach to the problem of heterogeneity of human tumor-cell populations. Br J Cancer 39: 570–577, 1979.Google Scholar
  72. 72.
    Vindelov LV, Hansen HH, Christensen IJ, Spange-Thomsen M, Hirsch FR, Hansen M, Nissen NI: Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow cytometric DNA analysis. Cancer Res 40: 4295–4300, 1980.PubMedGoogle Scholar
  73. 73.
    Tao TW, Burger MM: Nonmetastasizing variants selected from metastasizing melanoma cells. Nature 270: 437–438, 1977.PubMedGoogle Scholar
  74. 74.
    Brunson KW, Nicolson GL: Selection and biologic properties of malignant variants of a murine lymphosarcoma. JNCI 61: 1499–1503, 1978.PubMedGoogle Scholar
  75. 75.
    Raz A, McLellan WE, Hart IR, Bucana CD, Hoyer LC, Sela BA, Dragsten P, Fidler IJ: Cell surface properties of B16 melanoma variants with differing metastatic potential. Cancer Res 40: 1645–1651, 1980.PubMedGoogle Scholar
  76. 76.
    Reading CL, Belloni DN, Nicolson GL: Selection and in vivo properties of lectin-attachment variants of malignant murine lymphosarcoma cell lines. JNCI 64: 1241–1249, 1980.PubMedGoogle Scholar
  77. 77.
    Franks LM: Estrogen-treated prostatic cancer. Cancer 13: 490–501, 1960.PubMedGoogle Scholar
  78. 78.
    Sluyser M, Van Nie R: Estrogen receptor content and hormone-responsive growth of mouse mammary tumors. Cancer Res 34: 3252–3257, 1974.Google Scholar
  79. 79.
    Baylin SB, Abeloff MD, Wieman KC, Tomford JW, Ettinger DS: Elevated histaminase (diamine oxidase) activity in small-cell carcinoma of the lung. N Engl J Med 293: 1286–1290, 1975.PubMedGoogle Scholar
  80. 80.
    Sluyser M, Evers SG, DeGoey CC: Sex hormone receptors in mammary tumours of GR mice. Nature (Lond) 263: 386–389, 1976.Google Scholar
  81. 81.
    Baylin SB, Weisburger WR, Eggleston JC, Mendelshon G, Bearnen MA, Abeloff MD, Ettinger DS: Variable content of histaminase, L-dopa decarboxylase and calcitonin in small-cell carcinoma of the lung: Biologic and clinical implications. N Engl J Med 299: 105–110, 1978.PubMedGoogle Scholar
  82. 82.
    Barranco SC, Ho D, Derwinko B, Romsdahl MM, Humphrey RM: Differential sensitivities of human melanoma cells grown in vitro to arabinosylcytosine. Cancer Res 32: 2733–2736, 1972.PubMedGoogle Scholar
  83. 83.
    Barranco SC, Derwinko B, Humphrey RM: Differential response by human melanoma cells to 1,3-bis-(2-chloroethyl)-1-nitrosourea and bleomycin. Mutat Res 19: 277–280, 1973.Google Scholar
  84. 84.
    Hakansson L, Trope C: On the presence within tumors of clones that differ in sensitivity to cytostatic drugs. Acta Pathol Microbiol Scand [A] 82: 35–40, 1974.Google Scholar
  85. 85.
    Hakansson L, Trope C: Cell clones with different sensitivity to cytostatic drugs in methyl-cholanthrene-induced mouse sarcomas. Acta Pathol Microbiol Scand [A] 82:41–47,Google Scholar
  86. 86.
    Trope C, Hakansson L, Dencker H: Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cystostatic drugs. Neoplasma 22: 423–430, 1975.PubMedGoogle Scholar
  87. 87.
    Trope C: Different sensitivity to cytostatic drugs of primary tumor and metastasis of the Lewis carcinoma. Neoplasma 22: 171–180, 1975.PubMedGoogle Scholar
  88. 88.
    Fugmann RA, Anderson JC, Stoli R, Martin DS: Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. Cancer Res 37: 496–500, 1977.PubMedGoogle Scholar
  89. 89.
    Heppner GH, Dexter DL, DeNucci T, Miller FR, Calabresi P: Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. Cancer Res 38: 3758–3763, 1978.PubMedGoogle Scholar
  90. 90.
    Barranco SC, Hanenelt BR, Gea EL: Differential sensitivities of five rat hepatoma cell lines to anticancer drugs. Cancer Res 38: 656–660, 1978.PubMedGoogle Scholar
  91. 91.
    Lotan R: Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res 39: 1014–1019, 1979.PubMedGoogle Scholar
  92. 92.
    Lotan R, Nicolson GL: Heterogeneity in growth inhibition by β-trans-retinoic acid of metastatic B16 melanoma clones and in v/vo-selected cell variant lines. Cancer Res 39: 4767 - 4771, 1979.PubMedGoogle Scholar
  93. 93.
    Calabresi P, Dexter DL, Heppner GH: Clinical and pharmacological implications of cancer cell differentiation and heterogeneity. Biochem Pharmacol 28: 1933–1941, 1979.PubMedGoogle Scholar
  94. 94.
    Trope C, Aspergen K, Kullander S, Astredt B: Heterogeneous response of disseminated human ovarian cancers to cytostasis in vitro. Acta Obstet Gynecol Scand 58: 543–546, 1979.PubMedGoogle Scholar
  95. 95.
    Tsuruo T, Fidler IJ: Differences in drug sensitivity among tumor cells from parental tumors, selected variants, and spontaneous metastases. Cancer Res 41: 3058–3064, 1981.PubMedGoogle Scholar
  96. 96.
    Fidler IJ, Kripke ML: Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893–895, 1977.PubMedGoogle Scholar
  97. 97.
    Nicolson GL, Brunson KW: Organ specificity of malignant B16 melanoma; in vivo selection for organ preference of blood-borne metastasis. Cancer Res 20: 15–24, 1977.Google Scholar
  98. 98.
    Nicolson GL, Brunson KW, Fidler IJ: Specificity of arrest, survival, and growth of selected metastatic variant cell lines. Cancer Res 38: 4105–4111, 1978.PubMedGoogle Scholar
  99. 99.
    Fidler IJ, Cifone MA: Properties of metastatic and nonmetastatic cloned subpopulations of an ultraviolet-light-induced murine fibrosarcoma of recent origin. Am J Pathol 97: 633–648, 1979.PubMedGoogle Scholar
  100. 100.
    Liotta LA, Tryggvason K, Gabrisa A, Hart IR, Foltz CM: Metastatic potential correlated with enzymatic degradation of basement membrane collagen. Nature 284: 67–68, 1980.PubMedGoogle Scholar
  101. 101.
    Fidler IJ, Hart IR: The origin of metastatic heterogeneity in tumors. Eur J Cancer 17: 487–494, 1981.PubMedGoogle Scholar
  102. 102.
    Trope C: Different susceptibilities of tumor cell subpopulations to cytotoxic agents. In: Design of models for testing cancer therapeutic agents, Fidler IJ, White RJ (eds). New York: Van Nostrand, Inc., 1981, pp 64–79.Google Scholar
  103. 103.
    Baylin SB: Clonal selection and heterogeneity of human solid neoplasms. In: Design of models for testing cancer therapeutic agents, Fidler IJ, White RJ (eds). New York: Van Nostrand, Inc., 1981, pp 50–63.Google Scholar
  104. 104.
    Abeloff MD, Ettinger DS, Khouri NF, Lenhard RE: Intensive induction therapy for small cell carcinoma of the lung. Cancer Treat Rep 63: 519–524, 1979.PubMedGoogle Scholar
  105. 105.
    Livinston RB: Treatment of small cell carcinoma: Evaluation and future directions. Semin Oncol 5: 299–308, 1979.Google Scholar
  106. 106.
    Alexander P, Evans R: Endotoxin and double stranded RNA render macrophages cytotoxic. Nature 232: 76–78, 1971.Google Scholar
  107. 107.
    Hibbs JB Jr, Taintor RR, Chapman HA Jr, Weinberg JB: Macrophage tumor killing: Influence of the local environment. Science 197: 279–282, 1977.PubMedGoogle Scholar
  108. 108.
    Doc WF, Henson PM: Macrophage stimulation by bacterial lipopolysaccharides. J Exp Med 148: 544–556, 1978.Google Scholar
  109. 109.
    Pace JL, Russell SW: Activation of mouse macrophages for tumor cell killing: I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol 126: 1863–1868, 1981.PubMedGoogle Scholar
  110. 110.
    Peu G, Polentarutti N, Sessa C, Mangioni C, Mantovani A: Tumoricidal activity of macrophages isolated from human ascitic and solid ovarian carcinomas: Augmentation by interferon, lymphokines and endotoxin. Int J Cancer 28: 143–152, 1981.Google Scholar
  111. 111.
    Evans R: Specific and nonspecific activation of macrophages. In: Activation of macrophages: Proceedings of the 2nd Workshop Conference, Hoechst, Schloss Reisensburg, 25–26 October, 1972. Amsterdam: Excerpta Medica, 1974, pp 305–317.Google Scholar
  112. 112.
    Munder PG, Weltzien HV, Modolell M: Lysolecithin analogs: A new class of immunopotentiators. In: Immunopathology, Miescher PA (ed). New York: Grune & Stratton, 1977, pp 411–424.Google Scholar
  113. 113.
    Tarnowski GS, Mountain IM, Stock CC, Munder PG, Weltzier HL, Westphal O: Effects of lysolecithin and analogs on mouse ascites tumors. Cancer Res 38: 339–344, 1978.PubMedGoogle Scholar
  114. 114.
    Keller R, Jones VE: Role of activated macrophages and antibody in inhibition and enhancement of tumor growth in rats. Lancet 2: 847–849, 1971.PubMedGoogle Scholar
  115. 115.
    Hibbs JB, Lambert LH, Remington JS: Macrophage-mediated non-specific cytotoxicity: Possible role in tumor resistance. Nature New Biol 235: 48–50, 1972.PubMedGoogle Scholar
  116. 116.
    Cleveland RP, Meltzer MS, Lbau B: Tumor cytotoxicity in vitro by macrophages from mice infected with Mycobacterium bovis strain BCG. J Natl Cancer Inst 52: 1887–1895, 1974.PubMedGoogle Scholar
  117. 117.
    Kaplan AM, Morachan PS, Regelson W: Induction of macrophage-mediated tumor-cell cytotoxicity by pyran copolymer. J Natl Cancer Inst 52: 1919–1927, 1974.PubMedGoogle Scholar
  118. 118.
    Chirigos MA, Stylos WA: Immunomodulatory effect of various molecular-weight maleic anhydride-divinyl ether and other agents in vivo. Cancer Res 40: 1967–1972, 1980.PubMedGoogle Scholar
  119. 119.
    Juy D, Chedid L: Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci USA 72: 4105–4109, 1975.PubMedGoogle Scholar
  120. 120.
    Taniyama T, Holden HT: Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Immunol 48: 369–374, 1979.PubMedGoogle Scholar
  121. 121.
    Sone S, Fidler IJ: In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57: 42–50, 1981.PubMedGoogle Scholar
  122. 122.
    Schultz RM, Papamatheakis JD, Chirigos MA: Interferon; An inducer of macrophage activation by polyanions. Science 197: 674–676, 1977.PubMedGoogle Scholar
  123. 123.
    Boraschi D, Tagliabui A: Interferon-induced enhancement of macrophage-mediated tumor cytolysis and its difference from activation by lymphokines. Eur J Immunol 11: 110–114, 1981.PubMedGoogle Scholar
  124. 124.
    Kripke ML, Budmen MB, Fidler IJ: Production of specific macrophage-activating factor by lymphocytes from tumor-bearing mice. Cell Immunol 30: 341–352, 1976.Google Scholar
  125. 125.
    David JR: Macrophage activation by lymphocyte mediators. Fed Proc 34: 1730–1736, 1975.PubMedGoogle Scholar
  126. 126.
    Churchill WH, Piessens WF, Sulis CA, David JR: Macrophages activated as suspension cultures with lymphocyte mediators devoid of antigens become cytotoxic for tumor cells. J Immunol 115: 781–786, 1975.PubMedGoogle Scholar
  127. 127.
    Fidler IJ, Raz A: The induction of tumoricidal capacities in mouse and rat macrophages by lymphokines. In: Lymphokines, Pick E (ed). New York: Academic Press, 1981, pp 345–363.Google Scholar
  128. 128.
    Cohn ZA: The activation of mononuclear phagocytes: Fact, fancy and future. J Immunol 121: 813–816, 1978.PubMedGoogle Scholar
  129. 129.
    North RJ: The concept of the activated macrophage. J Immunol 121: 806–809, 1978.PubMedGoogle Scholar
  130. 130.
    Hibbs JB Jr: Discrimination between neoplastic and non-neoplastic cells in vitro by activated macrophages. J Natl Cancer Inst 53: 1487–1492, 1974.PubMedGoogle Scholar
  131. 131.
    Piessens WF, Churchill WH Jr: Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells. J Immunol 114: 293–299, 1975.PubMedGoogle Scholar
  132. 132.
    Fidler IJ: Recognition and destruction of target cells by tumoricidal macrophages. Isr J Med 14: 177–191, 1978.Google Scholar
  133. 133.
    Fidler IJ, Roblin RO, Poste G: In vitro tumoricidal activity of macrophages against virus-transformed lines with temperature-dependent transformed phenotypic characteristics. Cell Immunol 38: 131–146, 1978.PubMedGoogle Scholar
  134. 134.
    Fidler IJ, Poste G: Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. In: Seminars in immunopathology, Baldwin R (ed). In press, 1982.Google Scholar
  135. 135.
    Granger GA, Weiser RS: Homograft target cells: Specific destruction in vitro by contact interaction with immune macrophages. Science 145: 1427–1429, 1964.PubMedGoogle Scholar
  136. 136.
    Evans R, Alexander P: Mechanism of immunologically specific killing of tumor cells by macrophages. Nature 236: 168–170, 1972.PubMedGoogle Scholar
  137. 137.
    Keller R: Cytostatic elimination of syngeneic rat tumor cells in vitro by nonspecifically activated macrophages. J Exp Med 138: 625–644, 1973.PubMedGoogle Scholar
  138. 138.
    Keller R: Susceptibility of normal and transformed cell lines to cytostatic and cytocidal effects exerted by macrophages. J Natl Cancer Inst 56: 369–376, 1976.PubMedGoogle Scholar
  139. 139.
    Hibbs JB Jr: Macrophage nonimmunologic recognition: Target cell factors related to contact inhibition. Science 180: 868–869, 1973.PubMedGoogle Scholar
  140. 140.
    Meltzer MS, Tucker RW, Sanford KK, Leonard EJ: Interaction of BCG-activated macrophages with neoplastic and non-neoplastic cell lines in vitro: Quantitation of the cytotoxic reaction by release of initiated thymidine from prelabeled target cells. J Natl Cancer Inst 54: 1177–1186, 1975.PubMedGoogle Scholar
  141. 141.
    Norbury K, Fidler IJ: In vitro tumor cell cytotoxicity by syngeneic mouse macrophages: Methods for assaying cytotoxicity. J Immunol Methods 7: 109–121, 1975.PubMedGoogle Scholar
  142. 142.
    Raz A, Fogler WE, Fidler IJ: The effects of experimental conditions on the expression of in vitro mediated tumor cytotoxicity. Cancer Immunol Immunother 7: 157–163, 1979.Google Scholar
  143. 143.
    Meltzer MS, Tucker RW, Brever AC: Interaction of BCG-activated macrophages with neoplastic and nonneoplastic cell lines in vitro: Cinemicrographic analysis. Cell Immunol 17: 30–42, 1975.PubMedGoogle Scholar
  144. 144.
    Bucana C, Hoyer LC, Hobbs B, Breesman S, McDaniel M, Hanna MG Jr: Morphological evidence for the translocation of lysosomal organelles from cytotoxic macrophages into the cytoplasm of tumor target cells. Cancer Res 36: 4444–4458, 1976.PubMedGoogle Scholar
  145. 145.
    Hibbs JB Jr: Heterocytolysis by macrophages activated by bacillus Calmette-Guerin: Lysosome exocytosis into tumor cells. Science 184: 468–471, 1974.PubMedGoogle Scholar
  146. 146.
    Puvion F, Fray A, Halpern B: A cytochemical study of the in vitro interaction between normal and activated mouse peritoneal macrophages and tumor cells. J Ultrastruct Res 54: 95–108, 1975.Google Scholar
  147. 147.
    Miller ML, Stimmett JD, Clark LC Jr: Ultrastructure of tumoricidal peritoneal exudate cells stimulated in vivo by perfluorochemical emulsions. J Reticuloendothel Soc 27: 105–117, 1980.PubMedGoogle Scholar
  148. 148.
    Kaplan AM, Brown J, Collins JM, Morahan PS, Snodgrass MJ: Mechanism of macrophage-mediated tumor cell cytotoxicity. J Immunol 121: 1781–1789, 1978.PubMedGoogle Scholar
  149. 149.
    Allison AC: Macrophage activation and non-specific immunity. Int Rev Exp Pathol 18: 303–312, 1978.PubMedGoogle Scholar
  150. 150.
    Aksamit RR, Kim KJ: Macrophage cell lines produce a cytotoxin. J Immunol 122: 1785–1790, 1979.PubMedGoogle Scholar
  151. 151.
    Currie GA, Basham C: Differential arginine dependence and the selective cytotoxic effects of activated macrophages for malignant cells in vitro. Br J Cancer 39: 653–659, 1978.Google Scholar
  152. 152.
    Mclvoc KL, Weiser RS: Mechanisms of target cell destruction by alloimmune peritoneal macrophages: II. Release of a specific cytotoxin from interacting cells. Immunology 20: 315–322, 1971.Google Scholar
  153. 153.
    Pipen CE, Molvoc KL: Alloimmune peritoneal macrophages as specific effector cells: Characterization of specific macrophage cytotoxin. Cell Immunol 17: 423–430, 1975.Google Scholar
  154. 154.
    Sharma SF, Piessens WF, Middlebrook G: In vitro killing of tumor cells by soluble products of activated guinea pig peritoneal macrophages. Cell Immunol 49: 379–383, 1980.PubMedGoogle Scholar
  155. 155.
    Ferluga J, Schorlemmer HU, Baptista CC, Allison AC: Production of the complement cleavage product, C3a, by activated macrophages and its tumorolytic effects. Clin Exp Immunol 31: 512–517, 1978.PubMedGoogle Scholar
  156. 156.
    Stadecker MJ, Calderon J, Kainovsky MJ, Unanue ER: Synthesis and release of thymidine by macrophage. J Immunol 119: 1738–1743, 1978.Google Scholar
  157. 157.
    Nathan CF, Brukner LH, Silverstein SC, Cohn LA: Extracellular cytolysis by activated macrophages and granulocytes: I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med 149: 84–99, 1979.PubMedGoogle Scholar
  158. 158.
    Nathan CF, Silverstein SC, Brukner LH, Cohn LA: Extracellular cytolysis by activated macrophages and granulocytes: II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med 149: 110–113, 1979.Google Scholar
  159. 159.
    Adams DO: Effector mechanisms of cytolytically activated macrophages: I. Secretion of natural proteases and effect of protease inhibitors. J Immunol 124: 286–292, 1980.PubMedGoogle Scholar
  160. 160.
    Adams DO, Kao KJ, Farb R, Pizzo SV: Effector mechanisms of cytolytically activated macrophages: II. Secretion of a cytolytic factor by activated macrophages and its relationship to secreted neutral proteases. J Immunol 124: 293–300, 1980.PubMedGoogle Scholar
  161. 161.
    Kay MMB: Mechanism of removal of senescent cells by human macrophages in situ. Proc Natl Acad Sci USA 72: 3521–3525, 1975.PubMedGoogle Scholar
  162. 162.
    MacDonald RA, MacSween RNM, Pechet GS: Iron metabolism by reticuloendothelial cells in vitro: physical and chemical conditions, lipotrope deficiency, and acute inflammation. Lab Invest 21: 236–241, 1969.PubMedGoogle Scholar
  163. 163.
    Day AJ: The macrophage system, lipid metabolism and atherosclerosis. J Atherosclerosis Res 4: 117–131, 1964.Google Scholar
  164. 164.
    Nathan CF, Murray HW, Cohn LA: Current concepts: The macrophage as an effector cell. N Engl J Med 303: 622–626, 1980.PubMedGoogle Scholar
  165. 165.
    Cohn ZA: The structure and function of monocytes and macrophages. Adv Immunol 9: 163–189, 1968.PubMedGoogle Scholar
  166. 166.
    Van Furth R: Mononuclear phagocytes in immunity, infection and pathology, Oxford, Blackwell, 1975.Google Scholar
  167. 167.
    Nelson DS: Immunobiology of the macrophage. New York: Academic Press, 1976.Google Scholar
  168. 168.
    Fink MA: The macrophage in neoplasia. New York: Academic Press, 1976.Google Scholar
  169. 169.
    James K, McBride B, Stuart A: The macrophage and cancer. Edinburgh: University of Edinburgh Press, 1977.Google Scholar
  170. 170.
    Hibbs JB, Lambert LH, Remington JS: Control of carcinogenesis: A possible role for the activated macrophage. Science 177: 998–1000, 1972.PubMedGoogle Scholar
  171. 171.
    Evans R, Alexander P: Mechanisms of extracellular killing of nucleated mammalian cells by macrophages. In: The immunobiology of the macrophage, Nelson DS (ed). New York: Academic Press, 1976, pp 562–576.Google Scholar
  172. 172.
    Lurie H: Resistance to tuberculosis: experimental studies in native and acquired defense mechanisms. Cambridge: Harvard University Press, 1964.Google Scholar
  173. 173.
    Droller MJ, Remmington JS: A role for the macrophage in vivo and in vitro resistance to murine bladder tumor cell growth. Cancer Res 35: 49–53, 1975.PubMedGoogle Scholar
  174. 174.
    Norbury K, Kripke ML: Ultraviolet-induced carcinogenesis in mice treated with silica, trypan blue or pyran copolymer. J Reticuloendothel Soc 26: 827–837, 1979.PubMedGoogle Scholar
  175. 175.
    Jones PDE, Castro JE: Immunological mechanisms in metastatic spread and the antimetastatic effects of C. parvum. Br J Cancer 35: 519–527, 1977.PubMedGoogle Scholar
  176. 176.
    Sadler TE, Jones DDE, Castro JE: The effects of altered phagocytic activity on growth of primary and metastatic tumors. In: The macrophage and cancer, McBride JF, Stuart A (eds). Edinburgh: Econoprint, 1979, pp 115–163.Google Scholar
  177. 177.
    Mantovani A, Giavazzi R, Polentanitti N, Spreafico F, Gavattinni S: Divergent effects of macrophage toxins on growth of primary tumors and lung metastases in mice. Int J Cancer 25: 617–624, 1980.PubMedGoogle Scholar
  178. 178.
    Fidler IJ: Inhibition of pulmonary metastasis by intravenous injection of specifically activated macrophages. Cancer Res 34: 1074–1078, 1974.PubMedGoogle Scholar
  179. 179.
    Liotta LA, Gattozzi C, Kleinerman J, Saidel G: Reduction of tumor cell entry into vessels by BCG-activated macrophages. Br J Cancer 36: 639–641, 1977.PubMedGoogle Scholar
  180. 180.
    Fidler IJ, Fogler WE, Connor J: The rationale for the treatment of established experimental micrometastases with the injection of tumoricidal macrophages. In: Immunobiology and immunotherapy of cancer, Terry WD, Yamamura Y (eds). New York: Elsevier, 1979, pp 361–375.Google Scholar
  181. 181.
    Den Otter W, Dullens Hub FJ, Van Lovern H, Peils E: Anti-tumor effects of macrophages injected into animals: A review. In: The macrophage and cancer, James K, McBride B, Stuart A (eds). Edinburgh: Econoprint, 1977, pp 119–141.Google Scholar
  182. 182.
    Blarney RW, Crosby DL, Baker JM: Reticuloendothelial activity during the growth of rat sarcomas. Cancer Res 29: 335–337, 1969.Google Scholar
  183. 183.
    Old LJ, Clarke DA, Benacerraf B, Goldsmith M: The reticuloendothelial system and the neoplastic process. Science 88: 164–180, 1960.Google Scholar
  184. 184.
    Rhodes J: Altered expression of human monocyte Fc receptors in malignant disease. Nat¬ure 265: 253–255, 1977.Google Scholar
  185. 185.
    Rhodes J: Resistance of tumor cells to macrophages. Cancer Immunol Immunother 7: 211–215, 1980.Google Scholar
  186. 186.
    Bernstein ID, Zbar B, Rapp HJ: Impaired inflammatory response in tumor-bearing guinea pigs. J Natl Cancer Inst 49: 1641–1647, 1972.PubMedGoogle Scholar
  187. 187.
    Eccles SA, Alexander P: Sequestration of macrophages in growing tumors and its effect on the immunological capacity of the host. Br J Cancer 30: 42–49, 1974.PubMedGoogle Scholar
  188. 188.
    Meltzer MS, Stevenson MM: Macrophage function in tumor-bearing mice: Tumoricidal and chemotactic response of macrophages activated by infection with Mycobacterium bovis, strain BCG. J Immunol 118: 2176–2181, 1977.PubMedGoogle Scholar
  189. 189.
    Meltzer MS, Stevenson MM: Macrophage function in tumor-bearing mice: Dissociation of phagocytic and chemotactic responsiveness. Cell Immunol 35: 99–111, 1978.PubMedGoogle Scholar
  190. 190.
    Normann SJ, Sorkm E: Cell-specific defect in monocyte function during tumor growth. J Natl Cancer Inst 57: 135–140, 1976.Google Scholar
  191. 191.
    Snyderman R, Pike MC, Blaylock BL, Weinstein P: Effect of neoplasms on inflammation: Depression of macrophage accumulation after tumor implantation. J Immunol 116: 585–589, 1976.PubMedGoogle Scholar
  192. 192.
    Sone S, Fidler IJ: Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases. Cancer Res 41: 2401–2406, 1981.PubMedGoogle Scholar
  193. 193.
    Mantovani A: Effects on in vitro tumor growth of murine macrophages isolated from sarcoma lines differing in immunogenicity and metastasizing capacity. Int J Cancer 22: 741–747, 1978.PubMedGoogle Scholar
  194. 194.
    Russell SW, Mcintosh AT: Macrophages isolated from regressing Moloney sarcomas are more cytotoxic than those recovered from progressing sarcomas. Nature 268: 69–71, 1977.PubMedGoogle Scholar
  195. 195.
    Evans R: Tumor macrophages in host immunity to malignancies. In: The macrophage in neoplasia, Fink MA (ed). New York: Academic Press, 1976, pp 27–42.Google Scholar
  196. 196.
    Eccles SA: Macrophages and cancer. In: Immunological aspects of cancer, Castro JE (ed). Lancaster, England: MTP Press, 1978, pp 123–154.Google Scholar
  197. 197.
    Eccles SA, Alexander P: Macrophage content of tumors in relationship to metastatic spread. Nature 250: 667–669, 1974.PubMedGoogle Scholar
  198. 198.
    Talmadge JE, Key M, Fidler IJ: Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 126: 2245–2248, 1981.PubMedGoogle Scholar
  199. 199.
    Evans R, Lawler EM: Macrophage content and immunogenicity of C57BL/6J and BALB/cByJ methylcholanthrene-induced sarcomas. Int J Cancer 26: 831–835, 1980.PubMedGoogle Scholar
  200. 200.
    Evans R, Eidler DM: Macrophage accumulation in transplanted tumors is not dependent on host immune responsiveness or presence of tumor-associated rejection antigens. J Reticuloendothel Soc 30: 425–437, 1981.PubMedGoogle Scholar
  201. 201.
    Dvorak HR, Dickersin GR, Dvorak AM, Manseau EJ, Pyne K: Human breast carcinoma: Fibrin deposits and desmoplasia. Inflammatory cell type and distribution in microvasculature and infarction. JNCI 67: 335–345, 1981.PubMedGoogle Scholar
  202. 202.
    Key M, Talmadge JE, Fidler IJ: Lack of correlation between the progressive growth of spontaneous metastases and their content of infiltrating macrophages. J Reticuloendothel Soc, 32: 387–396, 1982.PubMedGoogle Scholar
  203. 203.
    Nash JRG, Price JE, Tarin D: Macrophage content and colony-forming potential in mouse mammary carcinomas. Br J Cancer 43: 478–485, 1981.PubMedGoogle Scholar
  204. 204.
    Mantovani A: In vitro effects on tumor cells of macrophages isolated from an early-passage chemically-induced murine sarcoma and from its spontaneous metastases. Int J Cancer 27:221–228, 1981.Google Scholar
  205. 205.
    Yoshida T, Cohen S: Lymphokine activity in vivo in relation to circulating monocyte levels and delayed skin reactivity. J Immunol 122: 1540–1546, 1972.Google Scholar
  206. 206.
    Papermaster BW, Holtermann OA, Rosner D, Klein E, Dao T, Djerassi I: Regressions produced in breast cancer lesions by a lymphokine fraction from a human lymphoid cell line. Res Commun Chem Pathol Pharmacol 8: 413–428, 1974.PubMedGoogle Scholar
  207. 207.
    Salvin SB, Younger JS, Nishio J, Neta R: Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl Cancer Inst 55: 1233–1236, 1975.PubMedGoogle Scholar
  208. 208.
    Poste G, Kirsh R: Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophage. Cancer Res 39: 2582–2590, 1979.PubMedGoogle Scholar
  209. 209.
    Allison AC: Model of action of immunological adjuvants. J Reticuloendothel Soc 26: 619–630, 1979.PubMedGoogle Scholar
  210. 210.
    Chedid L, Caulli L, Audibut F: Recent developments concerning muramyl dipeptide, a synthetic immunoregulating molecule. J Reticuloendothel Soc 26: 631–641, 1979.PubMedGoogle Scholar
  211. 211.
    Matter A: The effects of muramyl dipeptide (MDP) in cell-mediated immunity: A comparison between in vitro and in vivo systems. Cancer Immunol Immunother 6: 201–210, 1979.Google Scholar
  212. 212.
    Parant M, Parant F, Chedid L, Yapo A, Petit JF, Lederer E: Fate of the synthetic immunoadjuvant, muramyl dipeptide (14C-labelled) in the mouse. Int J Immunopharmacol 1: 35–41, 1978.Google Scholar
  213. 213.
    Poste G, Kirsh R, Fogler WE, Fidler IJ: Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res 39: 881–891, 1979.PubMedGoogle Scholar
  214. 214.
    Fogler WE, Raz A, Fidler IJ: In situ activation of murine macrophages by liposomes containing lymphokines. Cell Immunol 53: 214–219, 1980.PubMedGoogle Scholar
  215. 215.
    Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G: Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 40:4460–4466, 1980.PubMedGoogle Scholar
  216. 216.
    Allison AC, Gregoriadis G: Liposomes as immunological adjuvants. Nature 252:252–254, 1979.Google Scholar
  217. 217.
    Fidler IJ: Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 208:1469–1471, 1980.PubMedGoogle Scholar
  218. 218.
    Fidler IJ, Raz A, Fogler WE, Hoyer LC, Poste G: The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. Cancer Res 41:495–504, 1981.PubMedGoogle Scholar
  219. 219.
    Hart IR, Fogler WE, Poste G, Fidler IJ: Toxicity studies of liposome-encapsulated immunomodulators administered intravenously to dogs and mice. Cancer Immunol Immunother 10:157–166, 1981.Google Scholar
  220. 220.
    Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G: Involvement of macrophages in the eradication of established metastases produced by intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496–501, 1982.PubMedGoogle Scholar
  221. 221.
    Sone S, Poste G, Fidler IJ: Rat alveolar macrophages are susceptible to free and liposome-encapsulated lymphokines. J Immunol 124:2197–2202, 1980.PubMedGoogle Scholar
  222. 222.
    Fidler IJ: The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127:1719–1720, 1981.PubMedGoogle Scholar
  223. 223.
    Fidler IJ, Sone S, Fogler WE, Barnes Z: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78: 1680–1684, 1981.PubMedGoogle Scholar
  224. 224.
    Poste G, Kirsh R, Fidler IJ: Cell surface receptors for lymphokines. Cell Immunol 44:71–87, 1979.PubMedGoogle Scholar
  225. 225.
    Schabel FM Jr, Griswold DR Jr, Corbett TH, Lloyd HH: Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther A 1:411–435, 1977.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1983

Authors and Affiliations

  • William E. Fogler
  • Isaiah J. Fidler

There are no affiliations available

Personalised recommendations